| Original language | English |
|---|---|
| Journal | Annals of the rheumatic diseases |
| DOIs | |
| Publication status | Accepted/In press - 2019 Jan 1 |
Keywords
- DMARDs (biological)
- rheumatoid arthritis
- treatment
ASJC Scopus subject areas
- Immunology and Allergy
- Rheumatology
- Immunology
- Biochemistry, Genetics and Molecular Biology(all)
Cite this
Response to : Â € Comment on â € Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: The RRRR study, a randomised controlled trial' by Tanaka et al ' by Berkhout et al. / Tanaka, Yoshiya; Oba, Koji; Takeuchi, Tsutomu.
In: Annals of the rheumatic diseases, 01.01.2019.Research output: Contribution to journal › Letter
}
TY - JOUR
T1 - Response to
T2 - Â € Comment on â € Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: The RRRR study, a randomised controlled trial' by Tanaka et al ' by Berkhout et al
AU - Tanaka, Yoshiya
AU - Oba, Koji
AU - Takeuchi, Tsutomu
PY - 2019/1/1
Y1 - 2019/1/1
KW - DMARDs (biological)
KW - rheumatoid arthritis
KW - treatment
UR - http://www.scopus.com/inward/record.url?scp=85076475249&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85076475249&partnerID=8YFLogxK
U2 - 10.1136/annrheumdis-2019-216593
DO - 10.1136/annrheumdis-2019-216593
M3 - Letter
C2 - 31818809
AN - SCOPUS:85076475249
JO - Annals of the Rheumatic Diseases
JF - Annals of the Rheumatic Diseases
SN - 0003-4967
ER -